AzTrials
AzTrials

Upper Respiratory Tract InfectionNCT06140446

Effect of eHealth on AB Use of Children With Acute, Uncomplicated URTIs

A study testing FeverApp and DMT App in people with Upper Respiratory Tract Infection, run by Max Nieuwdorp at 1 site in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to test the effectiveness of two self-care eHealth applications in parents of children with uncomplicated upper respiratory tract infections (URTIs). Read more about this study

Who is it for?
Ages 3 months to 12 years
Conditions the study is for
Upper Respiratory Tract Infection
What is being tested?
FeverApp and DMT App
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
411 participants
Where
1 siteNetherlands
Study dates
Dec 2023to May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 months to 12 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Having a child aged 0-12 years old
  • Master the Dutch language
  • Having called the GP for their child aged 0-12 years having:
  • Fever (≥38 °C) AND
  • At least one of the following symptoms:
  • Acute cough
Show all 12Show fewer
  • Sore throat
  • Earache/runny ear
  • Nasal congestion/runny nose
  • Headache
  • Being screened by a triage specialist (GP practice assistant) and not being indicated for a GP/NP/PA visit
  • Not being included in the trial before

Who cannot join

  • The current URTI complaints of the child already exist longer than 2 weeks
  • The child who has a URTI
  • is younger than 3 months old
  • has asthma or another chronic or severe illness
  • has a history of pneumonia
  • has a history of complications or hospitalization from a previous URTI
Show all 9Show fewer
  • has Down Syndrome
  • has a less functioning immune system
  • The parent being very worried

Trial locations and contacts

1 site in 1 country.

Eefje Belt-van Zoen, MSc contact

+31648134012

belt.e@hsleiden.nl

Noortje van Steenbergen, MSc contact

+31618523072

steenbergen.van.n@hsleiden.nl

Netherlands1 site
  • Amsterdam UMC location AMC

    Amsterdam

Other trials in Netherlands

About this study

Official title: Effect of Two eHealth Applications on Antibiotic Use for Acute, Uncomplicated Upper Respiratory Tract Infections in Children: a Randomized Controlled Trial Among Parents in Dutch General Practice

The goal of this clinical trial is to test the effectiveness of two self-care eHealth applications in parents of children with uncomplicated upper respiratory tract infections (URTIs).

The main question it aims to answer is:

Read more
  • What is the effect of a self-management FeverApp and a self-care herbal medicine decision making tool (DMT) on reducing antibiotic use for acute, uncomplicated URTIs, among children in Dutch general practice?

Participants will:

  • Complete an online questionnaire at baseline
  • Use a self-care eHealth application for ten days (in the intervention groups)
  • Report symptom severity of the URTI of their child online at day 2, 5 an 7
  • Complete an online follow-up questionnaire at day 10
  • Collect two stool samples of their child at baseline and at day 10

Researchers will compare three groups to see if the Apps have an effect on recovery time and complications from URTIs, AB use, frequency of GP visits, and diversity of the gut microbiome:

  • Parents that will use an evidence based fever app additional to standard advices of their GP
  • Parents that will use an evidence based herbal medicine DMT additional to standard advices of their GP
  • A control group of parents who will receive just standard advices from their GP,
Read the detailed description

Rationale:

Antimicrobial resistance (AMR) is a complex and growing international public health problem with important consequences as increased mortality and high economic impact. Less inappropriate antibiotic (AB) prescription is one of the global strategies to reduce AMR. In primary care most inappropriate AB prescriptions are for acute, uncomplicated respiratory tract infections (URTIs). URTIs are among the most frequently seen complaints among children in general practice. ABs are only indicated for URTis in case of complications. Nevertheless, they are still often prescribed for uncomplicated cases. A reason for this could be worried parents parents requesting for an AB prescription for their child. In Dutch primary care, ABs can be prescribed by general practitioners (GPs), nurse practitioners (NPs) and physician assistants (PAs). Besides AMR, ABs can cause damage to the gut microbiome. Adequate fever (self) management and safe use of effective (self-care) herbal medicine (HM) are both expected to reduce AB use in mild, acute uncomplicated URTIs. Therefore, a (self-management) FeverApp and a (self-care) herbal medicine decision making tool (DMT App) were developed for parents in general practice.

Objectives:

The primary objective of this study is to investigate the effect of a self-management FeverApp and a self-care DMT App on reducing antibiotic use for acute, uncomplicated URTIs, among children in Dutch general practice. Secondary objectives are to examine (1) amount of apps-related complications and recovery time from acute, uncomplicated URTIs in comparison to standard GP advices, (2) the effect of apps use on reducing the number of GP practice visits and telephone consultations for acute, uncomplicated URTIs, and (3) the effects of apps use (reducing AB use) on diversity of the gut microbiome.

Study design:

The study design is a Randomized Controlled Trial (RCT) in six GP practices. There will be three study groups: (1) a group of parents who will be advised to use the FeverApp additional to advices from their GP practice, (2) a group of parents who will be advised to use the self-care DMT App additional to advices from their GP practice, and (3) a control group of parents who will only receive advices from their GP practice. Recruitment of parents will be done by the GP practice assistants of the participating practices, and selection and inclusion will be carried out by a research assistant from University of Applied Sciences Leiden (UAS Leiden). Randomization over the conditions will be done at random by the research assistant. This will result in parents assigned to either the Fever App group, the DMT App group or the control group. All included parents will, after receiving the participant information, fill out a baseline online questionnaire (including digital informed consent), and will collect a baseline stool sample of their child and save it in the freezer (T0). After that, parents in the intervention groups download and use the app they were assigned to, and all parents report (severity of) URTI symptoms of their child online at 2, 5 and 7 days (T1, T2 and T3) in an online form. Ten days after T0, all parents fill out a follow-up questionnaire, collect a second stool sample from their child, and save it in their own -20 degrees Celsius freezer (T4). At the end of the study, all of the stool samples will be picked up at home by research assistants from UAS Leiden, and will be transferred to Amsterdam University Medical Centre for the laboratory gut microbiome analysis.

Benefits, burden and risks:

The benefit of participating in the study, is that parents in the intervention groups will get extra support by means of the apps, on top of the advices that will be provided by the GP practice. For the control group there is no real benefit, besides contributing to less AB use among children in the future. The burden of this study lies in the fact that parents who participate, will have to fill out two online questionnaires within two weeks, report symptom severity online at two more timepoints, and will have to collect a stool sample of their child twice and save it in the freezer. Parents in the intervention groups will get the advice to download and use one of the two investigated apps. It will be their own decision to actually do this or not.

Participating in the study is safe, because only parents of children with mild, acute, uncomplicated URTIs will be involved. Furthermore, advices/care by the GP practice will be continued for all patients in the study, and the advices in the (self-management) fever app are in line with national fever guidelines. The only difference is that, based on the most recent insights on fever, the app encourages to keep the child warm in the first phase of fever. With regards to safety of the (self-care) DMT App, adverse events due to HM are rare. Moreover, the herbs that are advised on in the app are freely available (without prescription) in drugstores and pharmacies in the Netherlands. Therefore, using the (self-care) DMT App will make things safer rather than less safe, because parents in the HM group will get a trustworthy advice based on scientific evidence and safety regulations, instead of buying herbal medicine without an evidence-based decision-making tool (DMT) like they would normally do.

All participating parents will be advised to always go to the national website with GP advices in case of doubts about the health status of their child, and to call their GP practice, the ED (emergency department) or 112 in case of alarm symptoms. Furthermore, all parents are told to report complications from the URTI and/or adverse events (such as hospitalization) to the researchers. In case of complications or adverse events, they will be will go back to just receiving advices/care from their GP/NP/PA. Participating parents will use the apps in a test account, so no data will be collected by the apps. Also, the online questionnaires they fill out are anonymous, so the privacy of parents who participate is secured. Finally, parents can leave the study at any moment and go back to just receiving advices from their GP practice. There is no relation between (parents in) the different study groups.

Being tested
FeverApp, DMT App
Keywords
eHealth, Antibiotics, Gut microbiome, General practice
Medical subject headings
Respiratory Tract Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FeverAppDevice

    The (self-management) FeverApp contains evidence-based information about fever and how to deal with it, tailored (phase-oriented) fever advices, and the option to monitor the health status of the child during a fever episode. All information and advices are based on the clinical expertise of paediatricians and the most recent international literature on fever, and complement the Dutch national fever guidelines. It is expected that by letting the body fight the infection on its own in a safe way, less ABs are needed, and the immune system will get stronger leading to less future infections as well.

  • DMT AppDevice

    The (self-care) DMT App is a decision making tool (DMT) that can be used by parents to choose a safe and effective herbal medicine (HM) product to reduce symptoms of mild, acute uncomplicated URTIs in their child. The advices that the DMT App provides, are based on a systematic review (SR) of SRs on effectiveness of HM for URTIs, a SR on working mechanisms of the most promising herbs, a prescription rates study of HM for URTIs in 6 European countries, and current EMA status of the included herbs. No prescription from a doctor is needed for these products.

Study groups in NCT06140446
Study groupRoleWhat they receive
FeverApp groupExperimentalUse af a self-care FeverApp (containing fever advices and a monitoring function for their child with an uncomplicated URTI), additional to standard advices of the GP.
Receives: Device: FeverApp
DMT groupExperimentalUse of a self-care decision making tool (to choose a herbal medicinal product for their child with an uncomplicated URTI), additional to standard advices from their GP.
Receives: Device: DMT App
Control groupNo interventionJust standard advices from the GP for their child with an uncomplicated URTI.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Antibiotic use (yes/no)

    Antibiotic use of the child in the current URTI episode

    Measured: Self-reported10 days after inclusion in the study

Secondary outcomes (7)
  1. Normal recovery time from URTI

    Recovery of the URTI within 7 days (based on the clinical expertise of GPs)

    Measured: Self-reported 10 days after inclusion in the study

  2. Adverse events/complications

    Adverse events/complications from current URTI

    Measured: Self-reported 10 days after inclusion in the study

  3. GP visits

    Number of follow-up GP/NP/PA visits for the current URTI episode

    Measured: Self-reported 10 days after inclusion in the study

  4. Telephone consultations

    Number of follow-up telephone consultations for the current URTI episode of the child

    Measured: Self-reported 10 days after inclusion in the study

  5. Gut microbiome diversity

    Change in diversity of the gut microbiome (by means of stool samples)

    Measured: At baseline (inclusion) AND 10 days after inclusion in the study

  6. AB type

    Type of AB used in current URTI episode

    Measured: Self-reported at 10 days after inclusion in the study

  7. AB dosage

    AB dosage used in current URTI episode

    Measured: Self-reported at 10 days after inclusion in the study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Nov 2023
  2. Study startDec 2023 (estimated)
  3. Primary completionMay 2024 (estimated)
  4. Study completionMay 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
RCT
Masking
None (open label)
Enrolment
411 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06140446
Sponsor's protocol ID
NW2023-49
Status last verified
Nov 2023
First submitted
14 Nov 2023
Last updated
21 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Belt-van Zoen E, van Steenbergen N, Veldman L, Nieuwdorp M, Baars EW. Evaluating the effects of two parental self-management eHealth applications on antibiotic use, number of primary care visits and gut microbiota of febrile Dutch children with acute, uncomplicated upper respiratory tract infections: a study protocol for a randomised controlled trial. BMJ Open. 2025 Dec 19;15(12):e101463. doi: 10.1136/bmjopen-2025-101463.

    PubMed 41419287

Questions about this trial

What is this clinical trial studying?

A study testing FeverApp and DMT App in people with Upper Respiratory Tract Infection, run by Max Nieuwdorp at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Eefje Belt-van Zoen, MSc (+31648134012, belt.e@hsleiden.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Antibiotic use (yes/no) (time frame: Self-reported10 days after inclusion in the study). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06140446, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in